Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
autologous mesenchymal stem cells implantation · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| autologous mesenchymal stem cells implantation | PROCEDURE | - |
Inclusion Criteria: * ages 18 and 65. males not involved in active military duty. females- non child bearing potential. distal tibia third fracture without joint involvement. fracture treated by IM nail, percutaneous plating or external fixation. Exclusion Criteria: * active systemic or local inf...
Autologous mesenchymal stem cells implantation is an investigational cell therapy being studied for the treatment of tibial fracture, specifically distal tibial fractures. It involves implanting a patient's own mesenchymal stem cells to support bone healing. The therapy is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Autologous mesenchymal stem cells implantation is being developed by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker TEVA. The therapy is currently in Phase 1 clinical development for the treatment of tibial fracture.
Autologous mesenchymal stem cells implantation is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. A Phase 1 clinical trial for the treatment of tibial fracture has been completed.
Autologous mesenchymal stem cells implantation has one completed clinical trial, identified as NCT00250302, titled 'Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures.' This Phase 1 trial enrolled 24 participants with tibial fracture in Israel and was not blinded or controlled.
Autologous mesenchymal stem cells implantation is a specific form of mesenchymal stem cell therapy. The term 'autologous' indicates that the stem cells are derived from the patient's own body, rather than from a donor. This approach is being studied for its potential to treat tibial fractures.